Erschienen in:
Open Access
01.12.2012 | Oral presentation
From discovery of RANKL to clinical application of anti-human RANKL antibody
verfasst von:
Hisataka Yasuda, Yuriko Furuya, Kohji Uchida
Erschienen in:
Arthritis Research & Therapy
|
Sonderheft 1/2012
Einloggen, um Zugang zu erhalten
Excerpt
Osteoporosis is a common bone disease characterized by reduced bone and increased risk of fracture. In postmenopausal women osteoporosis results from bone loss attributable to estrogen deficiency. Receptor activator of nuclear factor-B ligand (RANKL) is a pivotal osteoclast differentiation factor [
1]. Discovery of RANKL has opened a new era in the understanding of mechanisms in osteoclast differentiation over the last decade. The discovery also results in the development of a fully human anti-RANKL neutralizing monoclonal antibody (called denosumab) and denosumab has been approved for the treatment of osteoporosis in Europe and the US. …